Figures
![Figure 1.](/tables/wjon779w-g001.jpg)
Figure 1. Ultrasound of the neck showing a thyroid mass suspicious of malignancy.
![Figure 2.](/tables/wjon779w-g002.jpg)
Figure 2. Computer tomography of the neck and chest showing a mass arising in the isthmus of thyroid gland and multiple pulmonary nodules in both lung fields.
![Figure 3.](/tables/wjon779w-g003.jpg)
Figure 3. PET-CT showing FDG-avid nodular lesion in the thyroid isthmus, multiple bilateral cervical nodes, calcified mediastinal and hilar mass, patchy uptake in liver and sclerotic changes in skeleton suspicious for osseous metastasis.
![Figure 4.](/tables/wjon779w-g004.jpg)
Figure 4. (A) Metastatic medullary carcinoma in the lung, under respiratory epithelium (× 40). (B) Higher power of metastatic medullary carcinoma in the lung (× 60). (C) Amyloid deposition in metastatic medullary carcinoma in the lung (× 60).
![Figure 5.](/tables/wjon779w-g005.jpg)
Figure 5. (A) Subcarinal lymph nodes positive for metastatic disease (× 40). (B) Synaptophysin stain on lymph node metastatis (× 40).
![Figure 6.](/tables/wjon779w-g006.jpg)
Figure 6. Computer tomography of the abdomen showing several hepatic metastasis, splenomegaly and abdominal adenopathy.
![Figure 7.](/tables/wjon779w-g007.jpg)
Figure 7. Both serum calcitonin and CEA levels following cabozantinib therapy. Y axis: serum calcitonin levels pg/mL; Y axis: serum CEA levels ng/mL.
![Figure 8.](/tables/wjon779w-g008.jpg)
Figure 8. PET-CT showing extensive metastatic disease involving the spine.
![Figure 9.](/tables/wjon779w-g009.jpg)
Figure 9. (A) Vertebral biopsy showing metastatic medullary thyroid carcinoma. (B) Synaptophysin stain on vertebral metastasis.
![Figure 10.](/tables/wjon779w-g010.jpg)
Figure 10. Computer tomography of the head and spine region showing left orbital metastasis and worsening spinal metastasis.
![Figure 11.](/tables/wjon779w-g011.jpg)
Figure 11. Osteonecrosis of the jaw (ONJ) secondary to bisphosphonates.
![Figure 12.](/tables/wjon779w-g012.jpg)
Figure 12. Serum calcitonin levels following cabozantinib therapy. Y-axis: serum calcitonin in pg/mL.